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Miglitol (MT) is an 𝛼-glucosidase inhibitor with a postmeal blood glucose level lowering effect that is used to treat type 2 diabetes.
In addition, 𝛼-cyclodextrin (𝛼CD) has been reported to inhibit increases in postmeal blood glucose. The aim of this study was
to prepare a freeze-dried product (FD) composed of MT and 𝛼CD or 𝛾CD (molar ratio of MT/𝛼CD = 1/1, MT/𝛾CD = 1/1) and to
evaluate the physicochemical properties and biological activity of the FD.ThePXRDprofile of FD exhibited a halo pattern, and char-
acteristic peaks derived fromMT, 𝛼CD, and 𝛾CDwere not observed.The TG-DTA results for FD indicated an increased weight loss
temperature and the absence of an endothermic peak forMT.TheNIR absorption spectrummeasurement suggested an intermolec-
ular interaction between MT and 𝛼CD or 𝛾CD in the FD. 1H-1H NOESY NMR spectroscopy (D2O) revealed an intermolecular
interaction in the FD. The results of the 𝛼-glucosidase activity inhibition test and the 𝛼-amylase activity inhibition test indicated
that the FD exhibited the same inhibition rate as MT alone and the effects of MT were not altered by the freeze-drying method.
1. Introduction
Recently, the incidence of diabetes has increased in developed
countries.This has been attributed to smoking, an inadequate
diet, and lack of exercise, and diabetes has become a major
cause of the increasing death rate [1]. According to the
International Diabetes Federation report, the world diabetes
population continues to increase and in 2015, 415 million
people were suffering from diabetes. For this reason, the
treatment of prediabetes by controlling blood glucose at levels
lower than that required for a diabetes diagnosis to prevent
the development of full blown diabetes has been gaining
attention.
Cyclodextrins (CDs) are cyclic dextrins currently used
as food additives. Recently, 𝛼CD was reported to lower
blood sugar levels. Specifically, 𝛼CD inhibited pancreatic
amylase activity [2] and suppressed increases in blood sugar
[3]. In addition, CDs solubilize, stabilize, and mask drugs
by inclusion in a complex. For example, formulation of an
inclusion complex made of itraconazole, a sparingly soluble
antifungal agent, and hydroxypropyl-𝛽CD [4] increased the
solubilization of the drug. Additionally, formulation of an
inclusion complex made of limaprost, a prostaglandin E1
derivative that is unstable tomoisture, and 𝛼-cyclodextrin [5]
increased the drug’s stability. Further, masking a drug with
cyclodextrin decreased the bitter taste of the drug [6].
The currently available 𝛼-glucosidase inhibitors include
acarbose (AB), voglibose (VB), and miglitol (MT). AB, VB,
and MT are used as therapeutic agents for type 2 diabetes.
Among them, AB inhibits 𝛼-amylase and 𝛼-glucosidase
activity. Additionally, VB and MT are widely used clinically
because their 𝛼-glucosidase inhibitory action is stronger than
that of AB. In particular, MT is different from the other two
drugs and is quickly absorbed in the upper part of the small
intestine. This characteristic suppresses the rise in blood
glucose level starting 30min after ameal and continuing until
2 h after a meal. MT is particularly effective at inhibiting the
increase in blood glucose at 1 h after meal.
Therefore, this study focused on MT and aimed to
develop a formulation that would provide an additive syn-
ergistic suppressive effect on blood glucose elevation by
forming a complex with 𝛼CD. In this report, inclusion
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Figure 1: Chemical structures of (a) miglitol, (b) acarbose, (c) 𝛼CD, (d) 𝛾CD.
complexes with MT were prepared using 𝛼CD and 𝛾CD.
In addition, the addictive effect of 𝛼CD and 𝛾CD with 𝛼-
glucosidase inhibitors was evaluated.
2. Materials and Methods
2.1. Materials. 𝛼CD and 𝛾CD were donated by Cyclo Chem
Co., Ltd. (Tokyo, Japan) and stored at a temperature of 40∘C
and relative humidity of 82% for 7 days before use. MT
was donated by SANWA KAGAKU KENKYUSHO Co., Ltd
(Figure 1). All other chemicals were of analytical grade and
obtained fromWako Pure Chemical Industries., Ltd.
2.2. Methods
2.2.1. Preparation of Physical Mixture. A physical mixture
(PM) of MT/𝛼CD and a PM of MT/𝛾CD at a molar ratio of
1/1 was prepared by blending the two compounds for 1min
using a vortex mixer.
2.2.2. Preparation of Freeze-Dried Product. Complexes were
formed using a freeze-dryingmethod.Themixtures prepared
with MT/𝛼CD = 1/1 and MT/𝛾CD = 1/1 were dissolved
in 100mL of purified water and prefrozen at −30∘C or
lower.Thereafter, the prefrozen product was freeze-dried in a
vacuum freeze-dryer (FZ-6modelmanufactured by ALS Co.,
Ltd.) for 24 h to produce the freeze-dried product (FD).
2.2.3. Powder X-Ray Diffraction (PXRD). Powder X-ray
diffraction was performed using an X-ray diffractometer
(MiniFlex II, Rigaku) with Cu radiation, a scan range of 2𝜃 =
5–40∘, and a scan rate of 4∘/min.The intensities of diffraction
were measured using a NaI scintillation counter coupled to a
discriminator.
2.2.4. Thermogravimetry/Differential Thermal Analyzer. The
thermal behavior of the samples was analyzed using a ther-
mogravimetry/differential thermal analyzer (Thermo plus
Evo, Rigaku) under a nitrogen flow rate of 200mL/min. The
samples were heated at a scanning rate of 5.0∘C/min from
30∘C to 350∘C.
2.2.5. Near Infrared (NIR) Absorption Spectrometry. Each
sample was filled in with a Fourier transform type near
infrared spectrometer (Buchi N-500: Nippon Buchi),
under conditions of a measurement wavelength of
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10000–4000 cm−1, a measuring time of 8 s, and a measuring
temperature of 25∘C with an interval of 1 nm of optical path.
2.2.6. 1H-1H Nuclear Overhauser Effect Spectroscopy (NOESY)
NMR Spectroscopy. Two-dimensional (2D) NOESY NMR
spectroscopy and selective 1D-NMR spectroscopy were per-
formed using an NMR spectrometer (Varian NMR System
700NB, Agilent) with a cold probe operating at 699.6MHz
and a D2O solution. The measurement conditions were as
follows: an acquisition time of 7.0 𝜇s, a pulse width of 90∘, a
relaxation delay of 0.267 s, a mixing time of 4.500 s, a fixed
delay of 1.500 s, and a temperature of 298K.
2.2.7. 𝛼-Glucosidase Activity Inhibition Test. One hundred
microliters of each test solution (MT, 𝛼CD, 𝛾CD, PM
(MT/𝛼CD), PM (MT/𝛾CD), FD (MT/𝛼CD), and FD
(MT/𝛾CD)) and 600𝜇L of 0.1mol/L maleate buffer (pH 6.0)
were added to 100 𝜇L of a substrate solution (1% maltose).
Thereafter, 200𝜇L of 𝛼-glucosidase solution (active solution,
inactive solution) was added and the solution was incubated
for 60min at 37∘C to allow an 𝛼-glucosidase reaction.
The reaction was stopped by heating the solution at 100∘C
for 15min. Thereafter, 10𝜇L of the reaction solution was
dispensed into a 96-well microplate and 200 𝜇L of Gluest
CII-Test Wako, coloring reagent (Wako Pure Chemical
Industries, Ltd.), was added and the solution was incubated
for 5min at 37∘C. After incubation, the absorbance was
measured using a microplate reader (Spectra Max 190,
Molecular Devices Japan Ltd.) at a wavelength of 505 nm.
To 2.0 g of rat acetone powder (intestinal acetone powder
from rats, Sigma-Aldrich), 20mL of 0.1mol/L maleic
acid buffer solution (pH 6.0) was added and the mixture
was homogenized for 1min. Thereafter, the mixture was
centrifuged and the supernatant was used as an𝛼-glucosidase
active solution. In addition, this solution was heated at 100∘C
for 15min to obtain an inert liquid. The 𝛼-glucosidase active
solution was used as a positive control and the inactive
solution was used as a negative control. For the test solution,
acarbose was used as the control agent. The IC50 value of
acarbose was calculated from the dose-response curves (not
given in this paper). The results indicated that the IC50 value
of acarbose was 87 𝜇g/mL, which was close to the value
reported by Yang et al. [7]. Therefore, the concentration of
MT was set by taking the ratio between 100mg of one dose of
acarbose and 50mg of one dose of MT. The concentrations
of PM (MT/𝛼CD), PM (MT/𝛾CD), FD (MT/𝛼CD), and FD
(MT/𝛾CD) were adjusted to be equal to that of MT alone.
In addition, the concentration of 𝛼CD was adjusted to be
equal to that of PM (MT/𝛼CD) and FD (MT/𝛼CD), and the
concentration of 𝛾CD was equal to that of PM (MT/𝛾CD)
and FD (MT/𝛾CD).
The 𝛼-glucosidase activity inhibition rate was calculated
using the following formula:
𝛼-glucosidase inhibition% = 100 − (𝐶 − 𝐷)
(𝐴 − 𝐵)
× 100, (1)
where 𝐴 is the glucose concentration in the positive control,
𝐵 is the glucose concentration in the negative control,𝐶 is the
glucose concentration obtained by adding the test solution
to the positive control, and 𝐷 is the glucose concentration
obtained by adding the test solution to the negative control.
2.2.8. 𝛼-Amylase Activity Inhibition Test. Fifty microliters of
each test solution (MT, 𝛼CD, 𝛾CD, PM (MT/𝛼CD), PM
(MT/𝛾CD), FD (MT/𝛼CD), and FD (MT/𝛾CD)) and 400 𝜇L
of phosphate buffered saline (pH 7.4) were added to 450 𝜇L
of a substrate solution (0.5% starch aqueous solution).There-
after, 100 𝜇L of 𝛼-amylase solution (active solution, inactive
solution) was added and the mixture was incubated for
20min at 37∘C to perform an 𝛼-amylase reaction. Thereafter,
500 𝜇L of DSN reagent (1% 3,5-dinitrosalicylic acid and 12%
potassium sodium tartrate in 0.4mol/L NaOH) was added
to the incubated solution and the mixture was heated at
100∘C for 15min to stop the reaction. The reaction solution
(200𝜇L) was then dispensed into a 96-well microplate and
the absorbance was ELISA-assayed at a wavelength of 540 nm
using a microplate reader (Spectra Max 190, Molecular
Devices Japan KK). To 16.5mg of porcine pancreatic-derived
𝛼-amylase (𝛼-amylase from porcine pancreas, 19.5 unite
amylase/mg, SIGMA), 100mL of phosphate buffered saline
was added. After ultrasonic treatment for 10min, the mixture
was centrifuged and the supernatant was used as an 𝛼-
amylase active solution. In addition, this solution was heated
at 100∘C for 15min to obtain an inert liquid. The 𝛼-amylase
active solution was used as a positive control and the inactive
solution as a negative control. For the test solution, acarbose
was used as a control agent. The IC50 value of acarbose was
calculated from the dose-response curves (not given in this
paper). The results indicated that the IC50 value of acarbose
was 20 𝜇g/mL, which was close to the value reported by
Wickramaratne et al. [8].Therefore, the concentration of MT
was set by taking the ratio between 100mg of one dose of
acarbose and 50mg of one dose of MT. The concentrations
of PM (MT/𝛼CD), PM (MT/𝛾CD), FD (MT/𝛼CD), and FD
(MT/𝛾CD) were adjusted to be equal to that of MT alone.
In addition, the concentration of 𝛼CD was adjusted to be
equal to that of PM (MT/𝛼CD) and FD (MT/𝛼CD), and the
concentration of 𝛾CD was adjusted to be equal to that of PM
(MT/𝛾CD) and FD (MT/𝛾CD).
The 𝛼-amylase activity inhibition rate was calculated
using the following formula:
𝛼-Amylase Inhibition% = 100 − (𝐶 − 𝐷)
(𝐴 − 𝐵)
× 100, (2)
where 𝐴 is the glucose concentration in the positive control,
𝐵 is the glucose concentration in the negative control,𝐶 is the
glucose concentration obtained by adding the test solution
to the positive control, and 𝐷 is the glucose concentration
obtained by adding the test solution to the negative control.
3. Results and Discussion
3.1. PXRD Measurement. PXRD was performed to examine
the crystalline state of MT and CDs in the FD (MT/𝛼CD)
and FD (MT/𝛾CD) preparations (Figure 2). Intact MT exhib-
ited characteristic diffraction peaks at 2𝜃 = 15.5∘ and 19.2∘.
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Figure 2: PXRD patterns of MT/𝛼CD and MT/𝛾CD systems. (a)
MT intact, (b) 𝛼CD, (c) 𝛾CD, (d) PM (MT/𝛼CD = 1/1), (e) PM
(MT/𝛾CD = 1/1), (f) FD (MT/𝛼CD = 1/1), (g) FD (MT/𝛾 CD = 1/1).
◼: MT original, I: 𝛼CD original, 󳵳: 𝛾 CD original.
𝛼CD exhibited characteristic diffraction peaks at 2𝜃 = 12.0∘,
14.1∘, 21.52∘. The PM (MT/𝛼CD) exhibited diffraction peaks
derived from 𝛼CD at 2𝜃 = 12.0∘, 14.1∘, 21.5∘ and MT at 2𝜃
= 19.2∘. However, FD (MT/𝛼CD) exhibited a halo pattern.
𝛾CD exhibited a characteristic diffraction peak at 2𝜃 = 9.1∘.
The PM (MT/𝛾CD) exhibited diffraction peaks derived from
𝛾CD at 2𝜃 = 9.10∘ and MT at 2𝜃 = 15.5∘ and 19.16∘. However,
FD (MT/𝛾CD) exhibited a halo pattern similar to that of
FD (MT/𝛼CD) and an amorphous state was observed. An
amorphous state observed during the PXRD measurement
of a solid dispersion of CD and a guest molecule suggests
that there is a possibility that CD and the guest molecule
formed an inclusion complex [9, 10]. From this fact, we
presumed that some interaction occurred in the crystalline
state during the freeze-drying preparation of FD (MT/𝛼CD)
and FD (MT/𝛾CD).
3.2. TG-DTA. An amorphous state was observed in FD
(MT/𝛼CD) and FD (MT/𝛾CD) during the PXRD measure-
ment. Therefore, a TG-DTA measurement was performed
to confirm the thermal behavior (Figures 3 and 4). For the
intact MT, thermal weight reduction was observed around
227∘C. Conversely, a thermal weight decrease was observed
at 252∘C and 246∘C for FD (MT/𝛼CD) and FD (MT/𝛾CD).
In addition, in the intact MT, an endothermic peak owing to
themelting point ofMTwas confirmed around 142∘C.Even in
the PM(MT/𝛼CD) andPM(MT/𝛾CD), an endothermic peak
owing to themelting point ofMTwas observed around 141∘C.
However, an endothermic peak owing to the melting point of
MT was not observed in FD (MT/𝛼CD) and FD (MT/𝛾CD).
The increase in the thermal weight reduction temperature
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Figure 3: TG curves ofMT/𝛼CD andMT/𝛾CD systems. (a)MT, (b)
𝛼CD, (c) 𝛾CD, (d) PM (MT/𝛼CD = 1/1), (e) PM (MT/𝛾CD = 1/1), (f)
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Figure 4: DTA curves of MT/𝛼CD and MT/𝛾CD systems. (a) MT,
(b) 𝛼CD, (c) 𝛾CD, (d) PM (MT/𝛼CD= 1/1), (e) PM (MT/𝛾CD= 1/1),
(f) FD (MT/𝛼CD = 1/1), (g) FD (MT/𝛾CD = 1/1).
and the disappearance of the endothermic peak of the guest
molecule indicated that an inclusion complex made of CD
and the guest molecule was formed [11, 12]. These changes
in thermal behavior suggested intermolecular interactions in
MT/𝛼CD and MT/𝛾CD lyophilizates. Incidentally, there was
no change in the results of PXRD and TG-DTAmeasurement
after a month of preparation of FD (MT/𝛼CD) and FD
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Figure 5: NIR absorption spectra of MT/𝛼CD systems and second-differentiation NIR absorption spectra of MT/𝛼CD systems ((b) alkyl
group, (c) alkyl group, and (d) hydroxy group).
(MT/𝛾CD) (not shown data). Therefore, the freeze-dried
product (MT/𝛼CD and MT/𝛾CD) presume is stable.
3.3. NIR. PXRD measurement and TG-DTA measurement
suggested inclusion complex formation in FD (MT/𝛼CD) and
FD (MT/𝛾CD). Therefore, to verify the detailed intermolec-
ular interaction, the NIR absorption spectrum was measured
(Figures 5 and 6).
The results of the NIR measurement indicated that
the -OH group was observed around 4800 cm−1 [13] and
6660 cm−1–7140 cm−1 [14]. In addition, the -CH2 group was
observed around 5800 cm−1 [15] and 8145 cm−1–9153 cm−1
[16]. From the results of the NIR measurement, a peak
derived from an -OH group appeared around 4800 cm−1 and
that from a -CH2 group appeared around 5800 cm
−1 and
8600 cm−1 for MT. In 𝛼CD alone, a peak derived from an -
OH group appeared around 4900 cm−1 (Figure 5(a)). In the
second derivative spectrum, the peak of the -CH2 group
around 8600 cm−1 (Figure 5(b)) and 5800 cm−1 (Figure 5(c))
of MT was broadened in FD (MT/𝛼CD). In addition, the
peak derived from the -OH group around 4800 cm−1 of
MT and the -OH group around 4900 cm−1 of 𝛼CD was
broadened (Figure 5(d)). A broadened or shifted peak in the
NIR measurement indicated that there were intermolecular
interactions between the drug and functional group [17].
This suggested that there were intermolecular interactions
between the -CH2 group and -OH group of MT and the -OH
group of 𝛼CD in FD (MT/𝛼CD).
In addition, in 𝛾CD alone, a peak derived from the
-OH group appeared around 7000 cm−1 (Figure 6(a)). In the
results of the second derivative spectrum, the peak of the
-OH group around 4800 cm−1 (Figure 6(e)) and the peak of
-CH2 group around 8600 cm
−1 (Figure 6(b)) and 5800 cm−1
(Figure 5(d)) for MT were broadened in FD (MT/𝛾CD).
In addition, the peak derived from the -OH group
around 7000 cm−1 of 𝛾CD shifted to the higher wave number
(Figure 6(c)). This suggested that there were intermolecular
interactions between the -CH2 group and the -OH group in
MT and the -OH group in 𝛾CD in FD (MT/𝛾CD).
Miglitol has a -CH2 group at the 6th position in its
side chain and at a cyclic structure. Therefore, in the NIR
measurement, it is impossible to determine whether the
-CH2 group is of the cyclic structure or the 6th position in
the side chain. Therefore, detailed examination by 2D-NMR
measurement is necessary.
3.4. 1H-1H NOESY NMR Spectroscopy. NIR measurement
indicated an intermolecular interaction between the -CH2
and -OH group of MT and the -OH group of 𝛼CD and
between the -CH2 and -OH group of MT and the -OH group
of 𝛾CD. Therefore, the detailed intermolecular interaction
was further evaluated. First, 1H-NMR measurement of MT
alone was conducted to confirm the attributions of MT. The
results indicated that the -CH (h) of MT exhibited two peaks
at 3.62 ppm (h1) and 3.72 ppm (h2) (Figure 7).Thereafter,
1H-
1HNOESYNMR spectroscopymeasurement was performed
(Figures 8 and 9). In FD (MT/𝛼CD), cross peaks were
observed between the peak for the -CH (h2: 3.72 ppm) in
MT and the H-3 (3.76 ppm) protons in 𝛼CD (Figure 8). In
general, it has been reported that by observing H-3, 5, and 6
protons of the CD cavity and protons of the guest molecule
using 1H-1H-NMR, the structure of the inclusion complex
6 Journal of Pharmaceutics
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can be elucidated [18]. In addition, from this result, a cross
peak between H-3 showing the wide edge of CD and the -CH
(h2: 3.72 ppm) in MT was observed in FD (MT/𝛼CD). This
suggested that the inclusion complex made of 𝛼CD and MT
was in a form covering the alkyl group of MT from the cavity
of a wide edge of CD with respect to the alkyl group of the
-CH (h) of MT.
Additionally, in FD (MT/𝛾CD), cross peaks were
observed between the peak for -CH (h1: 3.62 ppm, h2:
3.72 ppm) of MT and the H-3 (3.72 ppm) and H-6 (3.65 ppm)
protons of 𝛾CD (Figure 9). From this result, a cross peak
between H-3 showing the wide edge of CD and -CH (h2:
3.72 ppm) of MT was observed in FD (MT/𝛾CD). This
suggested that the inclusion complex made of 𝛾CD and MT
Journal of Pharmaceutics 7
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Figure 8: 1H-1H -NOESY NMR spectra of MT/𝛼CD system.
included a form covering the alkyl group of MT from the
cavity of a wide edge of CD with respect to the alkyl group
of the -CH (h) in MT. This confirmed that the inclusion
complex with MT was similar between that with 𝛼CD and
that with 𝛾CD with different cavity diameters.
3.5. 𝛼-Glucosidase Activity Inhibition Test. Inclusion com-
plex formation was confirmed for FD (MT/𝛼CD) and FD
(MT/𝛾CD). Because deterioration of bioactivity is an area
of concern for inclusion preparations, the MT in inclusion
complexes was tested for 𝛼-glucosidase activity (Table 1). For
intact MT, a 51.2% inhibition of 𝛼-glucosidase activity was
observed. In addition, FD (MT/𝛼CD) and FD (MT/𝛾CD)
exhibited inhibition rates of 56.2% and 56.6%, respectively,
which was similar to the inhibition rates observed with intact
MT. Inhibition of 𝛼-glucosidase activity was not observed in
𝛼CDor 𝛾CD.This indicated that the 𝛼-glucosidase inhibitory
activity depended on the concentration ofMT and confirmed
Table 1: Inhibitory activities 𝛼-glucosidase and 𝛼-amylase.
Percentage of inhibition
𝛼-Glucosidase 𝛼-Amylase
MT 51.2 ± 7.3 —
𝛼CD — 4.4 ± 2.5
𝛾CD — 3.1 ± 1.1
PM (MT/𝛼CD) 51.5 ± 10.2 0.1 ± 0.8
PM (MT/𝛾CD) 56.2 ± 6.8 3.2 ± 2.2
FD (MT/𝛼CD) 49.9 ± 7.4 2.8 ± 1.1
FD (MT/𝛾CD) 56.6 ± 4.9 1.3 ± 2.6
Values are expressed as mean ± standard deviation (𝑛 = 3). Each data value
showed statistically significant difference at 𝑝 value < 0.05 using Turkey’s
multiple comparison tests.
that the 𝛼-glucosidase inhibitory activity of MT in the
inclusion complex was sufficiently maintained.
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Figure 9: 1H-1H -NOESY NMR spectra of MT/𝛾CD system.
3.6. 𝛼-Amylase Activity Inhibition Test. 𝛼CD has been
reported to inhibit 𝛼-amylase activity. To confirm the influ-
ence on the inhibition of 𝛼-amylase activity by the formation
of these complexes, an 𝛼-amylase activity inhibition test was
conducted (Table 1). Intact MT did not inhibit 𝛼-amylase
activity. Conversely, 𝛼CD and 𝛾CD exhibited inhibition rates
of 4.41% and 3.10%. In addition, FD (MT/𝛼CD) and FD
(MT/𝛾CD) exhibited inhibition rates of 3.21% and 1.29%,
whichwere almost equal to the inhibition rates observedwith
𝛼CD and 𝛾CD alone.This was due to inhibition of 𝛼-amylase
activity by both 𝛼CD and 𝛾CD and indicated that the 𝛼-
amylase inhibitory activity of 𝛼CD and 𝛾CD in the prepared
complex was sufficiently maintained. The dose of CD used
to prepare the FD was very small compared with the dose
reported to affect the inhibition of 𝛼-amylase activity [19].
Therefore, the 𝛼-amylase activity rate was very low. In the
future, it will be necessary to confirm these results under
different conditions. Further investigation should evaluate
the effects on blood sugar in animal studies using these
preparations.
In this study, MT/𝛼CD andMT/𝛾CDwere evaluated, but
a preparation containing MT/𝛽CD should also be evaluated.
However, MT/𝛽CD is not as easily prepared by freeze-drying
asMT/𝛼CD andMT/𝛾CD.The cavity of 𝛽CD is hydrophobic
compared to 𝛼CD and 𝛾CD. On the other hand, MT of
a drug used as a guest molecule in this study is a water-
soluble drug. Therefore, MT/𝛽CD inclusion complex might
not be confirmed. In the future, we plan to develop a better
preparation method.
4. Conclusion
In this study, we prepared MT/𝛼CD complex and MT/𝛾CD
complex using a freeze-drying method. In addition, it was
confirmed that the structure of the inclusion complex differed
depending on the size of the CD ring. Furthermore, we found
that there was no influence on the inhibition of 𝛼-glucosidase
or 𝛼-amylase activity depending on the preparation process
used for the FD.
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